Psoriasis - Pipeline Review, H2 2016

 

Rating

4.7 Star Rating for report Psoriasis - Pipeline Review, H2 2016
4.7 / 5 stars rating
Pages: 699
Price: $2500.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
The report provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects.  

Description

Global Markets Direct's, 'Psoriasis - Pipeline Review, H2 2016', provides an overview of the Psoriasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8865IDBRheumatoid Arthritis - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8834IDBGranulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeli...Dec 2016
Report... 05IB-GMDHC8821IDBSicca Syndrome (Sjogren) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8820IDBHereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Defi...Dec 2016
Report... 05IB-GMDHC8720IDBAnaphylaxis - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8637IDBSystemic Lupus Erythematosus - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8641IDBLung Transplant Rejection - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8650IDBPemphigus Vulgaris - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8594IDBPeanut Allergy - Pipeline Review, H2 2016Oct 2016
Report... 05IB-GMDHC8582IDBHematopoietic Stem Cell Transplantation - Pipeline Review, H2 20...Oct 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-09-28 

Report: Psoriasis - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
Introduction 9
Psoriasis Overview 10
Therapeutics Development 11
Psoriasis - Therapeutics under Development by Companies 13
Psoriasis - Therapeutics under Investigation by Universities/Institutes 26
Psoriasis - Pipeline Products Glance 27
Psoriasis - Products under Development by Companies 31
Psoriasis - Products under Investigation by Universities/Institutes 48
Psoriasis - Companies Involved in Therapeutics Development 49
Psoriasis - Therapeutics Assessment 194
Drug Profiles 221
Psoriasis - Dormant Projects 626
Psoriasis - Discontinued Products 654
Psoriasis - Product Development Milestones 660
Appendix 670
 

List of Tables

List of Tables
Number of Products under Development for Psoriasis, H2 2016 39
Number of Products under Development for Psoriasis - Comparative Analysis, H2 2016 40
Number of Products under Development by Companies, H2 2016 42
Number of Products under Development by Companies, H2 2016 (Contd..1) 43
Number of Products under Development by Companies, H2 2016 (Contd..2) 44
Number of Products under Development by Companies, H2 2016 (Contd..3) 45
Number of Products under Development by Companies, H2 2016 (Contd..4) 46
Number of Products under Development by Companies, H2 2016 (Contd..5) 47
Number of Products under Development by Companies, H2 2016 (Contd..6) 48
Number of Products under Development by Companies, H2 2016 (Contd..7) 49
Number of Products under Development by Companies, H2 2016 (Contd..8) 50
Number of Products under Development by Companies, H2 2016 (Contd..9) 51
Number of Products under Development by Companies, H2 2016 (Contd..10) 52
Number of Products under Development by Companies, H2 2016 (Contd..11) 53
Number of Products under Investigation by Universities/Institutes, H2 2016 54
Comparative Analysis by Late Stage Development, H2 2016 55
Comparative Analysis by Clinical Stage Development, H2 2016 56
Comparative Analysis by Early Stage Development, H2 2016 57
Comparative Analysis by Unknown Stage Development, H2 2016 58
Products under Development by Companies, H2 2016 59
Products under Development by Companies, H2 2016 (Contd..1) 60
Products under Development by Companies, H2 2016 (Contd..2) 61
Products under Development by Companies, H2 2016 (Contd..3) 62
Products under Development by Companies, H2 2016 (Contd..4) 63
Products under Development by Companies, H2 2016 (Contd..5) 64
Products under Development by Companies, H2 2016 (Contd..6) 65
Products under Development by Companies, H2 2016 (Contd..7) 66
Products under Development by Companies, H2 2016 (Contd..8) 67
Products under Development by Companies, H2 2016 (Contd..9) 68
Products under Development by Companies, H2 2016 (Contd..10) 69
Products under Development by Companies, H2 2016 (Contd..11) 70
Products under Development by Companies, H2 2016 (Contd..12) 71
Products under Development by Companies, H2 2016 (Contd..13) 72
Products under Development by Companies, H2 2016 (Contd..14) 73
Products under Development by Companies, H2 2016 (Contd..15) 74
Products under Development by Companies, H2 2016 (Contd..16) 75
Products under Investigation by Universities/Institutes, H2 2016 76
Psoriasis - Pipeline by AbbVie Inc, H2 2016 77
Psoriasis - Pipeline by Abeome Corporation, H2 2016 78
Psoriasis - Pipeline by AbGenomics International, Inc., H2 2016 79
Psoriasis - Pipeline by Addex Therapeutics Ltd, H2 2016 80
Psoriasis - Pipeline by Advinus Therapeutics Ltd, H2 2016 81
Psoriasis - Pipeline by Affibody AB, H2 2016 82
Psoriasis - Pipeline by Albireo AB, H2 2016 83
Psoriasis - Pipeline by Almirall, S.A., H2 2016 84
Psoriasis - Pipeline by Alteogen Inc., H2 2016 85
Psoriasis - Pipeline by Amgen Inc., H2 2016 86
Psoriasis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016 87
Psoriasis - Pipeline by AnaptysBio, Inc., H2 2016 88
Psoriasis - Pipeline by ApoPharma Inc., H2 2016 89
Psoriasis - Pipeline by Arena Pharmaceuticals, Inc., H2 2016 90
Psoriasis - Pipeline by Argos Therapeutics, Inc., H2 2016 91
Psoriasis - Pipeline by Arrien Pharmaceuticals, LLC, H2 2016 92
Psoriasis - Pipeline by AstraZeneca Plc, H2 2016 93
Psoriasis - Pipeline by Athenex, Inc., H2 2016 94
Psoriasis - Pipeline by Aurigene Discovery Technologies Limited, H2 2016 95
Psoriasis - Pipeline by Aurinia Pharmaceuticals Inc, H2 2016 96
Psoriasis - Pipeline by Avexxin AS, H2 2016 97
Psoriasis - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016 98
Psoriasis - Pipeline by BioApex, s.r.o., H2 2016 99
Psoriasis - Pipeline by BIOCAD, H2 2016 100
Psoriasis - Pipeline by Biocon Limited, H2 2016 101
Psoriasis - Pipeline by BioLingus AG, H2 2016 102
Psoriasis - Pipeline by BioMAS Ltd., H2 2016 103
Psoriasis - Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016 104
Psoriasis - Pipeline by Bionomics Limited, H2 2016 105
Psoriasis - Pipeline by Bionovis SA, H2 2016 106
Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2016 107
Psoriasis - Pipeline by Brickell Biotech, Inc., H2 2016 108
Psoriasis - Pipeline by Bristol-Myers Squibb Company, H2 2016 109
Psoriasis - Pipeline by C4X Discovery Holdings PLC, H2 2016 110
Psoriasis - Pipeline by CalciMedica, Inc., H2 2016 111
Psoriasis - Pipeline by Can-Fite BioPharma Ltd., H2 2016 112
Psoriasis - Pipeline by Celgene Corporation, H2 2016 113
Psoriasis - Pipeline by Cell Medica Limited, H2 2016 114
Psoriasis - Pipeline by Cellceutix Corporation, H2 2016 115
Psoriasis - Pipeline by ChemoCentryx, Inc., H2 2016 116
Psoriasis - Pipeline by Chipscreen Biosciences Ltd, H2 2016 117
Psoriasis - Pipeline by ChironWells GmbH, H2 2016 118
Psoriasis - Pipeline by Clonz Biotech Private Limited, H2 2016 119
Psoriasis - Pipeline by Coherus BioSciences, Inc., H2 2016 120
Psoriasis - Pipeline by Compugen Ltd., H2 2016 121
Psoriasis - Pipeline by Convoy Therapeutics, Inc., H2 2016 122
Psoriasis - Pipeline by Creabilis SA, H2 2016 123
Psoriasis - Pipeline by Crescendo Biologics Limited, H2 2016 124
Psoriasis - Pipeline by Curapel Limited, H2 2016 125
Psoriasis - Pipeline by Cutanea Life Sciences, Inc., H2 2016 126
Psoriasis - Pipeline by Dermala Inc, H2 2016 127
Psoriasis - Pipeline by Domainex Limited, H2 2016 128
Psoriasis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H2 2016 129
Psoriasis - Pipeline by EA Pharma Co Ltd, H2 2016 130
Psoriasis - Pipeline by Eli Lilly and Company, H2 2016 131
Psoriasis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016 132
Psoriasis - Pipeline by Exicure, Inc., H2 2016 133
Psoriasis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016 134
Psoriasis - Pipeline by Forward Pharma A/S, H2 2016 135
Psoriasis - Pipeline by Gem Pharmaceuticals, LLC, H2 2016 136
Psoriasis - Pipeline by Genentech, Inc., H2 2016 137
Psoriasis - Pipeline by Genor BioPharma Co., Ltd., H2 2016 138
Psoriasis - Pipeline by GlaxoSmithKline Plc, H2 2016 139
Psoriasis - Pipeline by GlycoMar Limited, H2 2016 140
Psoriasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016 141
Psoriasis - Pipeline by HitGen LTD, H2 2016 142
Psoriasis - Pipeline by Huabo Biopharm Co., Ltd., H2 2016 143
Psoriasis - Pipeline by Hydra Biosciences, Inc., H2 2016 144
Psoriasis - Pipeline by iCo Therapeutics Inc., H2 2016 145
Psoriasis - Pipeline by Idera Pharmaceuticals, Inc., H2 2016 146
Psoriasis - Pipeline by Immune Pharmaceuticals Inc., H2 2016 147
Psoriasis - Pipeline by Immune Response BioPharma, Inc., H2 2016 148
Psoriasis - Pipeline by Immungenetics AG, H2 2016 149
Psoriasis - Pipeline by Innovent Biologics, Inc., H2 2016 150
Psoriasis - Pipeline by Jenrin Discovery, Inc., H2 2016 151
Psoriasis - Pipeline by Johnson & Johnson, H2 2016 152
Psoriasis - Pipeline by Kadmon Corporation, LLC, H2 2016 153
Psoriasis - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2016 154
Psoriasis - Pipeline by KPI Therapeutics, Inc., H2 2016 155
Psoriasis - Pipeline by Lead Pharma Holding B.V., H2 2016 156
Psoriasis - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 157
Psoriasis - Pipeline by LEO Pharma A/S, H2 2016 158
Psoriasis - Pipeline by Lipidor AB, H2 2016 159
Psoriasis - Pipeline by Lupin Limited, H2 2016 160
Psoriasis - Pipeline by Lycera Corp., H2 2016 161
Psoriasis - Pipeline by mAbxience S.A., H2 2016 162
Psoriasis - Pipeline by Maruho Co., Ltd., H2 2016 163
Psoriasis - Pipeline by Medestea Research & Production S.p.A., H2 2016 164
Psoriasis - Pipeline by MediGene AG, H2 2016 165
Psoriasis - Pipeline by Merck KGaA, H2 2016 166
Psoriasis - Pipeline by MetrioPharm AG, H2 2016 167
Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 168
Psoriasis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 169
Psoriasis - Pipeline by Mycenax Biotech Inc., H2 2016 170
Psoriasis - Pipeline by NeuClone Pty Ltd, H2 2016 171
Psoriasis - Pipeline by Nimbus Therapeutics, LLC, H2 2016 172
Psoriasis - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2016 173
Psoriasis - Pipeline by Novan, Inc., H2 2016 174
Psoriasis - Pipeline by Novartis AG, H2 2016 175
Psoriasis - Pipeline by Nuevolution AB, H2 2016 176
Psoriasis - Pipeline by Numedii, Inc., H2 2016 177
Psoriasis - Pipeline by Oncobiologics, Inc., H2 2016 178
Psoriasis - Pipeline by OSE Immunotherapeutics, H2 2016 179
Psoriasis - Pipeline by Panacea Biotec Limited, H2 2016 180
Psoriasis - Pipeline by Pfizer Inc., H2 2016 181
Psoriasis - Pipeline by Pharis Biotec GmbH, H2 2016 182
Psoriasis - Pipeline by Pharmedartis GmbH, H2 2016 183
Psoriasis - Pipeline by Phenex Pharmaceuticals AG, H2 2016 184
Psoriasis - Pipeline by Pieris Pharmaceuticals Inc, H2 2016 185
Psoriasis - Pipeline by PinCell srl, H2 2016 186
Psoriasis - Pipeline by Promius Pharma, LLC, H2 2016 187
Psoriasis - Pipeline by Protalix BioTherapeutics, Inc., H2 2016 188
Psoriasis - Pipeline by Prothena Corporation Plc, H2 2016 189
Psoriasis - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 190
Psoriasis - Pipeline by RedHill Biopharma Ltd., H2 2016 191
Psoriasis - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 192
Psoriasis - Pipeline by Sandoz International GmbH, H2 2016 193
Psoriasis - Pipeline by Sareum Holdings Plc, H2 2016 194
Psoriasis - Pipeline by Selvita S.A., H2 2016 195
Psoriasis - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H2 2016 196
Psoriasis - Pipeline by Shulov Innovative Science Ltd., H2 2016 197
Psoriasis - Pipeline by Sigmoid Pharma Limited, H2 2016 198
Psoriasis - Pipeline by Soligenix, Inc., H2 2016 199
Psoriasis - Pipeline by Spherium Biomed S.L., H2 2016 200
Psoriasis - Pipeline by Stemline Therapeutics, Inc., H2 2016 201
Psoriasis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016 202
Psoriasis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 203
Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 204
Psoriasis - Pipeline by SWITCH Biotech LLC, H2 2016 205
Psoriasis - Pipeline by Syntrix Biosystems, Inc., H2 2016 206
Psoriasis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 207
Psoriasis - Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016 208
Psoriasis - Pipeline by Telormedix SA, H2 2016 209
Psoriasis - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 210
Psoriasis - Pipeline by TheraMAB LLC, H2 2016 211
Psoriasis - Pipeline by Therapeutic Proteins International, LLC, H2 2016 212
Psoriasis - Pipeline by Therapix Biosciences Ltd., H2 2016 213
Psoriasis - Pipeline by UCB S.A., H2 2016 214
Psoriasis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 215
Psoriasis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016 216
Psoriasis - Pipeline by Wellstat Therapeutics Corporation, H2 2016 217
Psoriasis - Pipeline by XBiotech Inc, H2 2016 218
Psoriasis - Pipeline by XenoPort, Inc., H2 2016 219
Psoriasis - Pipeline by Yuhan Corporation, H2 2016 220
Psoriasis - Pipeline by Ziarco Pharma Ltd, H2 2016 221
Assessment by Monotherapy Products, H2 2016 222
Assessment by Combination Products, H2 2016 223
Number of Products by Stage and Target, H2 2016 225
Number of Products by Stage and Mechanism of Action, H2 2016 235
Number of Products by Stage and Route of Administration, H2 2016 246
Number of Products by Stage and Molecule Type, H2 2016 248
Psoriasis - Dormant Projects, H2 2016 654
Psoriasis - Dormant Projects (Contd..1), H2 2016 655
Psoriasis - Dormant Projects (Contd..2), H2 2016 656
Psoriasis - Dormant Projects (Contd..3), H2 2016 657
Psoriasis - Dormant Projects (Contd..4), H2 2016 658
Psoriasis - Dormant Projects (Contd..5), H2 2016 659
Psoriasis - Dormant Projects (Contd..6), H2 2016 660
Psoriasis - Dormant Projects (Contd..7), H2 2016 661
Psoriasis - Dormant Projects (Contd..8), H2 2016 662
Psoriasis - Dormant Projects (Contd..9), H2 2016 663
Psoriasis - Dormant Projects (Contd..10), H2 2016 664
Psoriasis - Dormant Projects (Contd..11), H2 2016 665
Psoriasis - Dormant Projects (Contd..12), H2 2016 666
Psoriasis - Dormant Projects (Contd..13), H2 2016 667
Psoriasis - Dormant Projects (Contd..14), H2 2016 668
Psoriasis - Dormant Projects (Contd..15), H2 2016 669
Psoriasis - Dormant Projects (Contd..16), H2 2016 670
Psoriasis - Dormant Projects (Contd..17), H2 2016 671
Psoriasis - Dormant Projects (Contd..18), H2 2016 672
Psoriasis - Dormant Projects (Contd..19), H2 2016 673
Psoriasis - Dormant Projects (Contd..20), H2 2016 674
Psoriasis - Dormant Projects (Contd..21), H2 2016 675
Psoriasis - Dormant Projects (Contd..22), H2 2016 676
Psoriasis - Dormant Projects (Contd..23), H2 2016 677
Psoriasis - Dormant Projects (Contd..24), H2 2016 678
Psoriasis - Dormant Projects (Contd..25), H2 2016 679
Psoriasis - Dormant Projects (Contd..26), H2 2016 680
Psoriasis - Dormant Projects (Contd..27), H2 2016 681
Psoriasis - Discontinued Products, H2 2016 682
Psoriasis - Discontinued Products (Contd..1), H2 2016 683
Psoriasis - Discontinued Products (Contd..2), H2 2016 684
Psoriasis - Discontinued Products (Contd..3), H2 2016 685
Psoriasis - Discontinued Products (Contd..4), H2 2016 686
Psoriasis - Discontinued Products (Contd..5), H2 2016 687
 

List of Figures

List of Figures
Number of Products under Development for Psoriasis, H2 2016 39
Number of Products under Development for Psoriasis - Comparative Analysis, H2 2016 40
Number of Products under Development by Companies, H2 2016 41
Number of Products under Investigation by Universities/Institutes, H2 2016 54
Comparative Analysis by Late Stage Development, H2 2016 55
Comparative Analysis by Clinical Stage Development, H2 2016 56
Comparative Analysis by Early Stage Products, H2 2016 57
Assessment by Monotherapy Products, H2 2016 222
Assessment by Combination Products, H2 2016 223
Number of Products by Top 10 Targets, H2 2016 224
Number of Products by Stage and Top 10 Targets, H2 2016 224
Number of Products by Top 10 Mechanism of Actions, H2 2016 234
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 234
Number of Products by Top 10 Routes of Administration, H2 2016 245
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 245
Number of Products by Top 10 Molecule Types, H2 2016 247
Number of Products by Stage and Top 10 Molecule Types, H2 2016 247
 

Scope


- The report provides a snapshot of the global therapeutic landscape of Psoriasis
- The report reviews pipeline therapeutics for Psoriasis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Psoriasis therapeutics and enlists all their major and minor projects
- The report assesses Psoriasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Psoriasis

 

Highlights

According to Global Markets Direct's, recently published report 'Psoriasis - Pipeline Review, H2 2016'; Psoriasis pipeline therapeutics constitutes close to 264 molecules. Out of which approximately 247 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, Global Markets Direct says; Psoriasis Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.

The report 'Psoriasis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 25, 39, 29, 2, 96, 37 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 7 molecules, respectively.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Immunology 
Pages: 699 

Companies Featured

AbbVie Inc Abeome Corporation AbGenomics International, Inc. Addex Therapeutics Ltd Advinus Therapeutics Ltd Affibody AB Albireo AB Almirall, S.A. Alteogen Inc. Amgen Inc. Anacor Pharmaceuticals, Inc. AnaptysBio, Inc. ApoPharma Inc. Arena Pharmaceuticals, Inc. Argos Therapeutics, Inc. Arrien Pharmaceuticals, LLC AstraZeneca Plc Athenex, Inc. Aurigene Discovery Technologies Limited Aurinia Pharmaceuticals Inc Avexxin AS Betta Pharmaceuticals Co. Ltd. BioApex, s.r.o. BIOCAD Biocon Limited BioLingus AG BioMAS Ltd. Biomics Biotechnologies Co., Ltd. Bionomics Limited Bionovis SA Boehringer Ingelheim GmbH Brickell Biotech, Inc. Bristol-Myers Squibb Company C4X Discovery Holdings PLC CalciMedica, Inc. Can-Fite BioPharma Ltd. Celgene Corporation Cell Medica Limited Cellceutix Corporation ChemoCentryx, Inc. Chipscreen Biosciences Ltd ChironWells GmbH Clonz Biotech Private Limited Coherus BioSciences, Inc. Compugen Ltd. Convoy Therapeutics, Inc. Creabilis SA Crescendo Biologics Limited Curapel Limited Cutanea Life Sciences, Inc. Dermala Inc Domainex Limited Dr. August Wolff GmbH & Co. KG Arzneimittle EA Pharma Co Ltd Eli Lilly and Company Epirus Biopharmaceuticals, Inc. Exicure, Inc. Foamix Pharmaceuticals Ltd. Forward Pharma A/S Gem Pharmaceuticals, LLC Genentech, Inc. Genor BioPharma Co., Ltd. GlaxoSmithKline Plc GlycoMar Limited Grupo Ferrer Internacional, S.A. HitGen LTD Huabo Biopharm Co., Ltd. Hydra Biosciences, Inc. iCo Therapeutics Inc. Idera Pharmaceuticals, Inc. Immune Pharmaceuticals Inc. Immune Response BioPharma, Inc. Immungenetics AG Innovent Biologics, Inc. Jenrin Discovery, Inc. Johnson & Johnson Kadmon Corporation, LLC KaloBios Pharmaceuticals, Inc. KPI Therapeutics, Inc. Lead Pharma Holding B.V. Lee's Pharmaceutical Holdings Limited LEO Pharma A/S Lipidor AB Lupin Limited Lycera Corp. mAbxience S.A. Maruho Co., Ltd. Medestea Research & Production S.p.A. MediGene AG Merck KGaA MetrioPharm AG Mitsubishi Tanabe Pharma Corporation Momenta Pharmaceuticals, Inc. Mycenax Biotech Inc. NeuClone Pty Ltd Nimbus Therapeutics, LLC NovaLead Pharma Pvt. Ltd. Novan, Inc. Novartis AG Nuevolution AB Numedii, Inc. Oncobiologics, Inc. OSE Immunotherapeutics Panacea Biotec Limited Pfizer Inc. Pharis Biotec GmbH Pharmedartis GmbH Phenex Pharmaceuticals AG Pieris Pharmaceuticals Inc PinCell srl Promius Pharma, LLC Protalix BioTherapeutics, Inc. Prothena Corporation Plc Provectus Biopharmaceuticals, Inc. RedHill Biopharma Ltd. Rigel Pharmaceuticals, Inc. Sandoz International GmbH Sareum Holdings Plc Selvita S.A. Shanghai Celgen Bio-Pharmaceutical Co., Ltd. Shulov Innovative Science Ltd. Sigmoid Pharma Limited Soligenix, Inc. Spherium Biomed S.L. Stemline Therapeutics, Inc. sterna biologicals Gmbh & Co KG Sucampo Pharmaceuticals, Inc. Sun Pharma Advanced Research Company Ltd. SWITCH Biotech LLC Syntrix Biosystems, Inc. Takeda Pharmaceutical Company Limited Tasly Pharmaceutical Group Co., Ltd. Telormedix SA Teva Pharmaceutical Industries Ltd. TheraMAB LLC Therapeutic Proteins International, LLC Therapix Biosciences Ltd. UCB S.A. Valeant Pharmaceuticals International, Inc. Vitae Pharmaceuticals, Inc. Wellstat Therapeutics Corporation XBiotech Inc XenoPort, Inc. Yuhan Corporation Ziarco Pharma Ltd

 

Reasons to buy this report


- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Psoriasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8865IDBRheumatoid Arthritis - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8834IDBGranulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeli...Dec 2016
Report... 05IB-GMDHC8821IDBSicca Syndrome (Sjogren) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8820IDBHereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Defi...Dec 2016
Report... 05IB-GMDHC8720IDBAnaphylaxis - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8637IDBSystemic Lupus Erythematosus - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8641IDBLung Transplant Rejection - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8650IDBPemphigus Vulgaris - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8594IDBPeanut Allergy - Pipeline Review, H2 2016Oct 2016
Report... 05IB-GMDHC8582IDBHematopoietic Stem Cell Transplantation - Pipeline Review, H2 20...Oct 2016

Psoriasis - Pipeline Review, H2 2016

Report 05IB-GMDHC8494IDB has a rating of 94 percent
Figure of merit assessment for report 05IB-GMDHC8494IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7198

Taxonomy Location

The taxonomy on the left shows the ancestors of the Immunology node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Immunology

Immunology

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Psoriasis - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8494IDB

 
Licence: Single User
Price: $2500.00
 
VAT: 0.0% 
Total: $2500.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [2.71213s]

--